-
Founded in:
2000-06-26 -
Country:
China -
Address:
No. 1, Xianyao Road, Xianju County, Taizhou City, Zhejiang Province -
Tax NO.:
913300007047892221 -
Registered Funds:
989.204866 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Rocuronium bromide |
Muscle relaxants, used to relax skeletal muscles during general anesthesia
More
Muscle relaxants, used to relax skeletal muscles during general anesthesia |
119302-91-9 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Mifepristone |
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone for receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy.
More
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone for receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy. |
84371-65-3 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Mifepristone |
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone for receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy.
More
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone for receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy. |
84371-65-3 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Mifepristone |
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. They can significantly increase the sensitivity of the pregnant uterus to prostaglandins. Small doses of mifepristone sequentially combined with prostaglandin drugs can achieve satisfactory results in terminating early pregnancy.
More
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. They can significantly increase the sensitivity of the pregnant uterus to prostaglandins. Small doses of mifepristone sequentially combined with prostaglandin drugs can achieve satisfactory results in terminating early pregnancy. |
84371-65-3 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Testosterone propionate |
No specific pharmacological effects mentioned
More
No specific pharmacological effects mentioned |
57-85-2 | 13 |